The EPS beat is a one-time artifact—focus on the pipeline catalysts: bota-vec regulatory submissions (U.S., EU, UK, Japan) and AAV2-hAQP1 Phase 2 data in Q2 2027. The $100M offering and $25M J&J payment are already priced; watch for IND filing for Ribo-Leptin later this year and Phase 3 start for AAV-GAD.
Price Chart
Executive Summary
MeiraGTx reported Q1 2026 EPS of $0.19, a 142% beat vs consensus of -$0.45, on revenue of $0.3M (well below the $17.0M consensus). The headline EPS beat is driven by non-operating items (foreign currency loss, interest income/expense) and a narrow revenue base, not operational strength. The quarter's strategic highlights—reacquisition of bota-vec from J&J for $25M upfront, $100M equity offering, and FDA Breakthrough Therapy Designation for AAV2-hAQP1—are the real catalysts, positioning the company for potential regulatory filings in the next 2 years.
Key Financial Metrics
Key Facts
- Q1 2026 EPS $0.19 vs consensus -$0.45 (142% beat); revenue $0.3M vs consensus $17.0M (miss due to completion of J&J PPQ services)
- Reacquired bota-vec (XLRP gene therapy) from J&J for $25M upfront; J&J eligible for mid-teens royalty on global net sales starting mid-2029
- Completed $100M equity offering (11.1M shares at $9.00) in April 2026; cash + tax incentives + offering proceeds expected to fund operations into H2 2028
- FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 (radiation-induced xerostomia); Phase 2 AQUAx2 pivotal data readout on track for Q2 2027
- Net loss $46.3M ($0.57/share) vs $40.0M ($0.51/share) in Q1 2025; operating expenses flat at ~$41M
- Cash and equivalents $71.5M at March 31, 2026; plus $14.7M tax incentive receivable
Financial Impact
EPS beat of $0.64 vs consensus; revenue miss of $16.7M vs consensus; $100M equity offering strengthens balance sheet; $25M upfront payment for bota-vec reacquisition
Risk Factors
- Revenue base near zero post-J&J PPQ completion; no near-term product revenue until potential bota-vec approval
- Dilution from $100M offering (11.1M shares, ~14% of pre-offering shares outstanding)
- Clinical trial risks: bota-vec Phase 3 LUMEOS data already presented but regulatory approval not guaranteed; AAV2-hAQP1 Phase 2 data still 12 months away
- Debt repayment obligations: $25M due June 2026 and $50M due July 2027 to Perceptive Credit
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294852 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 144 | $10.82 | awaiting T+60 | — | $9.18 (−15.16%) |
Sep 24, 2026 4w ago | 3 | $10.91 | awaiting T+60 | — | $9.18 (−15.86%) |
Sep 23, 2026 4w ago | 8-K | $11.75 | awaiting T+60 | — | $9.18 (−21.87%) |
Aug 18, 2026 9w ago | 144 | $14.97 | awaiting T+60 | — | $9.18 (−38.68%) |
Aug 13, 2026 10w ago | 8-K | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Aug 13, 2026 10w ago | Press Release | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Jul 7, 2026 16w ago | 8-K | $14.66 $11.00 | ▼ −24.97% | ▼ −26.96% | $9.18 (−37.38%) |
May 19, 2026 22w ago | 144 | $9.58 $13.52 | ▲ +41.13% | ▲ +36.12% | $9.18 (−4.18%) |
May 14, 2026 23w ago | 8-K | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
May 14, 2026 23w ago | Press Release | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers